COGT
NASD Cogent Biosciences, Inc.$30.08 ↑ +0.00 (+0.00%) Trading Up from the previous close of $30.08, $0.58 below the day’s high of $30.66
- YTD change
- -15.32%
- vs 20-day SMA
- -6.03%
- vs 200-day SMA
- -17.00%
Price ranges
Price & Performance
-6.87 (-18.59%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 31.2% away from all-time highs of $43.73
- COGT is down 15% since the beginning of the year
- COGT is up 93% over the past 12 months
- COGT is down 12% over the past 1 month
- 10% of all COGT investors are betting against COGT
COGT reads neutral: price sits below both the 20- and 200-day averages, the 12-month move is +93.1%.
- Previous minute
- +$0.00
- Last hour
- +$0.03
- Last 5 days
- -6.06%
- vs 8-day SMA
- -3.57%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
Cogent Biosciences, Inc. is a biotechnology company, which engages in the development of precision therapies for genetically defined diseases. It focuses on CGT9486, a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation and other mutations in KIT exon 17. The company was founded by Charles Wilson and Dario Campana in March 2014 and is headquartered in Waltham, MA.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.
